Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
This section is Partnership Content suppliedThe content in this section is supplied by GlobeNewswire for the purposes of distributing press...









